Last reviewed 2026-04-20 · How we verify

Chewing Prasugrel LD

Sheba Medical Center · FDA-approved active Small molecule Quality 0/100

Chewing Prasugrel LD is a Small molecule drug developed by Sheba Medical Center. It is currently FDA-approved.

At a glance

Generic name	Chewing Prasugrel LD
Sponsor	Sheba Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chewing Prasugrel LD CI brief — competitive landscape report
Chewing Prasugrel LD updates RSS · CI watch RSS
Sheba Medical Center portfolio CI

Frequently asked questions about Chewing Prasugrel LD

What is Chewing Prasugrel LD?

Chewing Prasugrel LD is a Small molecule drug developed by Sheba Medical Center.

Who makes Chewing Prasugrel LD?

Chewing Prasugrel LD is developed and marketed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).

What development phase is Chewing Prasugrel LD in?

Chewing Prasugrel LD is FDA-approved (marketed).

Manufacturer: Sheba Medical Center — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing